RxDoctor Payments Data

Ronald Sher, MD

Cardiovascular Disease · Reisterstown, MDNPI 1447211586

Payments from drug & device makers

$5,009in general payments, 2019–2025

Across 238 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$895
  • Johnson & Johnson$553
  • E.r. Squibb & Sons, L.L.C.$455
  • Novo Nordisk$399
  • Merck$305
  • Pfizer$277
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$2004%
  • Food & beverage$4,79596%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,009 in reported general payments places this provider in the 65th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$644,385
Medicare patients
678
Services billed
2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$336,849
EntrestoSacubitril/Valsartan130$162,234
XareltoRivaroxaban45$62,268
JardianceEmpagliflozin52$43,805
FarxigaDapagliflozin Propanediol57$37,248
Repatha SureclickEvolocumab39$29,049
BrilintaTicagrelor13$11,927
Ranolazine ErRanolazine32$7,590
Rosuvastatin Calcium208$5,987
VascepaIcosapent Ethyl11$5,173
Ezetimibe47$2,484
Atorvastatin Calcium141$2,257
Metoprolol Succinate106$1,708
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$1,584
Nebivolol Hcl33$1,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$277$336,849308 claims
NovartisEntresto$895$162,234130 claims
Johnson & JohnsonXarelto$553$62,26845 claims
AstraZenecaFarxiga, Brilinta$167$49,17570 claims
Boehringer IngelheimJardiance$225$43,80552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Reisterstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →